News | April 03, 2022
JBCPL buys Azmarda trademark for India at Rs 246 crore
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Augnito in association with Japanese company Fujifilm enables voice recognition within their radiology information system platform
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
This has further strengthened its manufacturing presence in the United States of America
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Subscribe To Our Newsletter & Stay Updated
